CA2459622A1 - Compositions et methodes pour restaurer la sensibilite aux antagonistes de her2 lors d'un traitement - Google Patents

Compositions et methodes pour restaurer la sensibilite aux antagonistes de her2 lors d'un traitement Download PDF

Info

Publication number
CA2459622A1
CA2459622A1 CA 2459622 CA2459622A CA2459622A1 CA 2459622 A1 CA2459622 A1 CA 2459622A1 CA 2459622 CA2459622 CA 2459622 CA 2459622 A CA2459622 A CA 2459622A CA 2459622 A1 CA2459622 A1 CA 2459622A1
Authority
CA
Canada
Prior art keywords
pcdgf
antagonist
her2
erbb2
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2459622
Other languages
English (en)
Other versions
CA2459622C (fr
Inventor
Ginette Serrero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A&G Pharmaceutical Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2459622A1 publication Critical patent/CA2459622A1/fr
Application granted granted Critical
Publication of CA2459622C publication Critical patent/CA2459622C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2459622A 2003-08-01 2004-02-27 Compositions et methodes pour restaurer la sensibilite aux antagonistes de her2 lors d'un traitement Expired - Fee Related CA2459622C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49153603P 2003-08-01 2003-08-01
US60/491,536 2003-08-01

Publications (2)

Publication Number Publication Date
CA2459622A1 true CA2459622A1 (fr) 2005-02-01
CA2459622C CA2459622C (fr) 2016-12-13

Family

ID=34135125

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2459622A Expired - Fee Related CA2459622C (fr) 2003-08-01 2004-02-27 Compositions et methodes pour restaurer la sensibilite aux antagonistes de her2 lors d'un traitement

Country Status (1)

Country Link
CA (1) CA2459622C (fr)

Also Published As

Publication number Publication date
CA2459622C (fr) 2016-12-13

Similar Documents

Publication Publication Date Title
RU2528884C2 (ru) Лечение опухолей с помощью антитела к vegf
KR101280267B1 (ko) Egf 수용체 에피토프 펩타이드 및 이의 용도
BR112019025188A2 (pt) Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
TWI630916B (zh) 供治療或預防人表皮生長因子受體-3(her-3)相關疾病之藥料和方法
RU2689779C2 (ru) Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo
US6927203B1 (en) Treatment of metastatic disease
BR112019020508A2 (pt) anticorpos biespecíficos de ligação a erbb-2 e erbb3 para utilização no tratamento de células que possuem um gene de fusão nrg1
ES2426916T3 (es) Composiciones y procedimientos para restaurar la sensibilidad al tratamiento con antagonistas de HER2
KR102428254B1 (ko) 난소암의 검출 및 치료를 위한 조성물 및 방법
JP2014012006A (ja) Her−3に対して誘導された抗体及びその使用
US8445219B2 (en) Method of determination of receptor binding saturation effected by monoclonal antibodies
WO2020221198A1 (fr) Anticorps bispécifique à double sites her2 pour immunothérapie antitumorale
KR20050072744A (ko) 암 조절 방법
CA2459622C (fr) Compositions et methodes pour restaurer la sensibilite aux antagonistes de her2 lors d'un traitement
WO2025140324A1 (fr) Utilisation d'un anticorps anti-pd-1 combiné à un agent chimiothérapeutique dans le traitement de tumeurs
EA046932B1 (ru) Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство
HK1091141B (en) Compositions and methods for restoring sensitivity to treatment with her2 antagonists
BR112018067522B1 (pt) Anticorpo monoclonal isolado e sua variante, sequência de polinucleotídeos, plasmídeo, composição farmacêutica e uso da mesma
HK1134441B (en) Tumor therapy with an anti-vegf antibody

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200227